[HTML][HTML] Engineering mesoporous silica nanoparticles for drug delivery: where are we after two decades?

M Vallet-Regí, F Schüth, D Lozano, M Colilla… - Chemical Society …, 2022 - pubs.rsc.org
The present review details a chronological description of the events that took place during
the development of mesoporous materials, their different synthetic routes and their use as …

Tumor abnormality-oriented nanomedicine design

Q Zhou, J Xiang, N Qiu, Y Wang, Y Piao, S Shao… - Chemical …, 2023 - ACS Publications
Anticancer nanomedicines have been proven effective in mitigating the side effects of
chemotherapeutic drugs. However, challenges remain in augmenting their therapeutic …

Supramolecular cancer nanotheranostics

J Zhou, L Rao, G Yu, TR Cook, X Chen… - Chemical Society …, 2021 - pubs.rsc.org
Among the many challenges in medicine, the treatment and cure of cancer remains an
outstanding goal given the complexity and diversity of the disease. Nanotheranostics, the …

Gold complexes in anticancer therapy: From new design principles to particle‐based delivery systems

G Moreno‐Alcántar, P Picchetti… - Angewandte Chemie …, 2023 - Wiley Online Library
The discovery of the medicinal properties of gold complexes has fuelled the design and
synthesis of new anticancer metallodrugs, which have received special attention due to their …

Controlled anti-cancer drug release through advanced nano-drug delivery systems: Static and dynamic targeting strategies

FM Kashkooli, M Soltani, M Souri - Journal of controlled release, 2020 - Elsevier
Advances in nanomedicine, including early cancer detection, targeted drug delivery, and
personalized approaches to cancer treatment are on the rise. For example, targeted drug …

Extracellular vesicles versus synthetic nanoparticles for drug delivery

KW Witwer, J Wolfram - Nature Reviews Materials, 2021 - nature.com
Cell-released biological nanoparticles, that is, extracellular vesicles (EVs), are emerging
drug carriers with high complexity. EV-based drug delivery exploits intrinsic mechanisms for …

[HTML][HTML] Current approaches of nanomedicines in the market and various stage of clinical translation

X Shan, X Gong, J Li, J Wen, Y Li, Z Zhang - Acta Pharmaceutica Sinica B, 2022 - Elsevier
Compared with traditional drug therapy, nanomedicines exhibit intriguing biological features
to increase therapeutic efficiency, reduce toxicity and achieve targeting delivery. This review …

Nanoparticle-based medicines in clinical cancer therapy

S Wang, K Cheng, K Chen, C Xu, P Ma, G Dang… - Nano Today, 2022 - Elsevier
Anti-cancer drugs with various mechanisms emerge in succession, but most of free
therapeutics are accompanied by some disadvantages, such as poor safety and …

Progress, challenges, and future of nanomedicine

C Zhang, L Yan, X Wang, S Zhu, C Chen, Z Gu, Y Zhao - Nano Today, 2020 - Elsevier
Nanotherapeutics exhibit unique advantages in clinical outcomes compared with
conventional small molecular drugs. The past three decades have seen intensive research …

Applications and challenges of ultra-small particle size nanoparticles in tumor therapy

J Xu, M Song, Z Fang, L Zheng, X Huang… - Journal of Controlled …, 2023 - Elsevier
With the development of nanotechnology, nanomedicines are widely used in tumor therapy.
However, biological barriers in the delivery of nanoparticles still limit their application in …